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Abstract Leukemia inhibitory factor (LIF) enhanced mast cell
growth in a mast cell/3T3 fibroblast co-culture system, however
the precise mechanisms have not been defined. Western blot
analysis showed that bone marrow-derived mast cells failed to
express both LIF receptor (LIFR) and gp130, whereas 3T3
fibroblasts expressed both LIFR and gp130. This result indicates
that the activity of LIF for mast cell growth is mediated by 3T3
fibroblasts. Signal transducer and activator of transcription
(Stat) 3-transfected 3T3 fibroblasts enhanced mast cell growth.
In addition, dominant-negative Stat3-transfected fibroblasts
blocked LIF-mediated mast cell growth in the co-culture system.
In conclusion, LIF-induced mast cell growth in the co-culture
system is mediated by an indirect pathway via 3T3 fibroblasts
through activating Stat3 signaling pathway in 3T3 fibro-
blasts. ß 2000 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Mast cells are tissue-residing cells which play a key role in
some host-defense mechanisms as well as in IgE-mediated
immediate-type hypersensitivity reaction. Mast cells originate
from hematopoietic stem cells in the bone marrow [1], how-
ever, their development is characteristic when compared with
other hematopoietic lineages, such as basophils and eosino-
phils. Mast cell precursors di¡erentiate from the hemato-
poietic stem cells under strong in£uence of a stromal cell-de-
rived growth factor, stem cell factor (SCF) [2]. The precursor
is released from bone marrow, and further di¡erentiates into
mature mast cells after reaching tissues by tissue-oriented
mechanisms: in rodents, the precursor di¡erentiates into mu-
cosal mast cell by T cell-derived cytokine, interleukin (IL)-3,
IL-4, IL-9 and IL-10 or into connective tissue-type mast cell
by stromal cell-mediated cytokine, SCF.
In skin, mast cells reside in the dermal layer closely asso-
ciated with dermal ¢broblasts, and regulate microvascular cir-
culation through release of a series of mediators and cyto-
kines. Although SCF expressed on dermal ¢broblasts plays
a key role in the development of mast cells, the mechanisms
that regulate mast cell proliferation or di¡erentiation in
pathological conditions of the skin are not fully understood.
As an in vitro model of skin mast cells, the mast cell/¢broblast
co-culture system has been used to investigate the mechanisms
of mast cell di¡erentiation [3]. Recent studies have revealed
that ¢broblasts have an essential role for mast cell di¡erentia-
tion in the mast cell/¢broblast co-culture system [4,5]. On the
other hand, our previous study also de¢ned that a potent
¢broblast growth factor, platelet-derived growth factor, en-
hances mast cell proliferation in the co-culture system not
directly but via ¢broblasts, indicating that activation of ¢bro-
blasts is important for mast cell growth [6]. In addition, ¢bro-
blast-activating cytokines, IL-1K and tumor necrosis factor-K,
also have mast cell growth-enhancing activity in the co-culture
system through induction of prostaglandins [7]. Furthermore,
by analyzing the conditioned medium of squamous cell carci-
noma cell line (KCMH-1) cells for mast cell growth-enhancing
activity, we identi¢ed leukemia inhibitory factor (LIF) as a
potent mast cell growth-enhancing factor [8]. The mode of
action of LIF for mast cell growth-enhancement might also
be indirect and mediated by ¢broblasts. In the present study,
we investigated the role of LIF receptor (LIFR) and its signal-
ing pathway in ¢broblasts to understand the mechanisms of
LIF-mediated mast cell growth-enhancement.
2. Materials and methods
2.1. Cells
Bone marrow-derived mast cells (BMMC) were prepared from
6-week-old male mice (WBB6F1-+/+) according to the method de-
scribed previously [9]. Brie£y, bone marrow cells were cultured in
K-MEM (Gibco BRL, Rockville, MD, USA) containing 10% fetal
calf serum (FCS), 100 U/ml penicillin G and 100 Wg/ml streptomycin
(complete K-MEM) supplemented with 100 WM 2-mercaptoethanol,
5 ng/ml of recombinant mouse IL-3 (RpD Systems, Minneapolis,
MN USA) and 2 ng/ml of recombinant mouse IL-4 (RpD), and
cultured at 37‡C in a humidi¢ed atmosphere of 5% CO2 in air.
Non-adherent cells were collected by centrifugation and resuspended
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in fresh medium every 7 days. After 4 weeks, more than 95% of the
non-adherent cells were stained positively with alcian blue. NIH/3T3
¢broblasts (3T3 ¢broblasts) were obtained from The American Type
Culture Collection (CRL1658), and maintained in DMEM containing
10% calf serum, 100 U/ml penicillin G and 100 Wg/ml streptomycin.
2.2. Mast cell/3T3 ¢broblast co-culture
BMMC/3T3 ¢broblast co-culture was performed as described pre-
viously [9]. Brie£y, 2U104 3T3 ¢broblasts suspended in 0.5 ml of
complete K-MEM were seeded in each well of four-well multidishes
(Nunc A/S, Roskilde, Denmark), and cultured until con£uence. At
reaching con£uence, the medium was aspirated and 3U104 BMMC
suspended with 500 Wl of complete K-MEM containing various con-
centrations of recombinant mouse LIF (RpD) were added. The cells
were cultured at 37‡C in a humidi¢ed atmosphere of 5% CO2 in air
and the culture medium was changed every 2 days.
2.3. Mast cell counting in co-culture
Adherent cells in the co-cultures were dispersed by incubation in
trypsin-EDTA solution (Gibco BRL) for 10 min at 37‡C, followed by
addition of one tenth volume of FCS. The dispersed cells were washed
twice with phosphate-bu¡ered saline (PBS) and resuspended in 1 ml of
PBS containing 1% bovine serum albumin. Total number of cells in
the suspension was determined using an improved Neubauer hemocy-
tometer. Aliquots of cell suspensions were also spun in a cytocentri-
fuge (1500 rpm for 1 min) and resulting cell preparations on slide-
glasses were stained with alcian blue. The alcian blue-positive cells
(mast cells) in a culture dish were calculated using the following for-
mula: number of mast cells/dish = AUC/B, where A is total number of
cells in a culture dish; B total number of cells in a cytocentrifuge
specimen; and C number of alcian blue-positive cells in the same
specimen.
2.4. Determination of histamine content in co-culture
Cultured cells in each well were denatured by adding 0.25 N
HClO4, and insoluble proteins were precipitated by centrifugation at
12 000Ug at 4‡C for 10 min. Histamine concentration was assayed
with automated £uorometric high performance liquid chromatogra-
phy system (Tosoh Corporation, Tokyo, Japan) as described by Tsur-
uta et al. [10].
2.5. Western blot analysis
Cells (3T3 ¢broblasts and BMMC) were lysed in the sample bu¡er
(62.5 mM Tris^HCl, pH 6.8, 2% sodium dodecyl sulfate, 10% glycer-
ol, 50 mM dithiothreitol, 0.1% bromophenol blue) and electrophores-
ed by the method of Laemmli [11] with 5^20% polyacrylamide gel
(Atto Corporation, Tokyo, Japan). The proteins were transferred to
a polyvinylidene di£uoride membrane (Immobilon-P, Millipore, Bed-
ford, MA, USA). The membrane was incubated with rabbit anti-
mouse LIFR polyclonal antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) or rabbit anti-mouse gp130 polyclonal antibody
(Santa Cruz). After washed with TTBS, the membranes were incu-
bated with horseradish peroxidase (HRP)-conjugated anti-rabbit IgG
antibody. The reacted antibodies were visualized by using ECL
(Amersham Pharmacia Biotech, Buckinghamshire, UK) under a lumi-
nescent image analyzer (LAS-1000 plus, Fuji Photo Film Co., Ltd.,
Tokyo, Japan).
To detect LIF-induced tyrosine phosphorylation of LIFR and
gp130, subcon£uent cultures of 3T3 ¢broblasts in 35 mm dishes
were washed twice with PBS and stimulated with 100 ng/ml of LIF
for indicated intervals. Immunoprecipitations were performed as pre-
viously described [12]. Brie£y, cells were lysed in the lysis bu¡er (20
mM Tris^HCl, pH 7.4, 150 mM NaCl, 10% glycerol, 1% NP-40, 1 mM
phenylmethylsulfonyl £uoride, 0.15 U/ml aprotinin, 10 mM EDTA,
10 Wg/ml leupeptin, 100 mM sodium £uoride, 2 mM sodium
orthovanadate) at 4‡C for 30 min. Cell lysates were clari¢ed by cen-
trifuging for 10 min at 10 000Ug at 4‡C and incubated with anti-
mouse gp130 polyclonal antibody for 1 h at 4‡C. Protein G-Sepharose
4FF (Amersham Pharmacia Biotech) was used to collect the antigen^
antibody complexes. These immunoprecipitants were analyzed by im-
munoblotting using HRP-conjugated anti-phosphotyrosine antibody
(4G10) (Upstate Biotechnology, Lake Placid, NY, USA). For detec-
tion of tyrosine phosphorylation of the signal transducer and activa-
tor of transcription (Stat) 3 induced by LIF, cells were lysed and
analyzed using PhosphoPlus0 Stat3 (Tyr705) Antibody kit (New Eng-
land BioLabs, Beverly, MA, USA) according to the manufacturer’s
instructions.
2.6. Establishment of dominant-negative Stat3-stable transformants
The expression vector encoding hemagglutinin peptide (HA)-tagged
Stat3 (pEF-Bos-HA-Stat3) was a gift from Dr. Nakajima (Depart-
ment of Immunology, Osaka City University Graduate School of
Medicine, Osaka, Japan). The mutageneses for dominant-negative
Stat3, Glu434/435 to Ala (Stat3D) and Tyr705 to Phe (Stat3F) [13],
were performed by QuikChange0 Site-Directed Mutagenesis kit (Stra-
tagene, La Jolla, CA, USA) according to the manufacturer’s instruc-
tions, using the mutagenic primers as follows: Stat3D: sense primer
5P-GCC TCC TTG ATC GTG ACT GCG GCG CTG CAC CTG
ATC ACC TTC G-3P, antisense primer 5P-CGA AGG TGA TCA
GGT GCA GCG CCG CAG TCA CGA TCA AGG AGG C-3P ;
Stat3F: sense primer 5P-CCA GGT AGT GCT GCC CCG TTC
CTG AAG ACC AAG TTC ATC TG-3P, antisense primer 5P-CAG
ATG AAC TTG GTC TTC AGG AAC GGG GCA GCA CTA CCT
GG-3P. 3T3 ¢broblasts (1U106) were transfected with 19.5 Wg of pEF-
Bos (a gift from Dr. Nagata, Department of Genetics, Osaka Univer-
sity Medical School, Osaka, Japan), pEF-Bos-HA-Stat3, pEF-Bos-
HA-Stat3D or pEF-Bos-HA-Stat3F together with 0.5 Wg of pSV2neo
(Clontech Laboratories, Palo Alto, CA, USA) by electroporation, and
the transfected cells were selected with 1 mg/ml G418. The exogenous
expression of HA-tagged proteins of each stable transformant was
tested by Western blot analysis using anti-HA-tag polyclonal antibody
(MBL, Nagoya, Japan).
3. Results
3.1. LIF indirectly enhanced mast cell growth in the mast
cell/3T3 ¢broblast co-culture system
When BMMC were cultured in the co-culture system in the
presence of a series of concentrations of LIF, LIF increased
both mast cell number and total histamine content in a dose
dependent manner (Fig. 1). The increase of total histamine
contents in the wells was parallel to the increase of mast cell
number, thus total histamine contents were utilized for mast
cell proliferation assay in subsequent experiments. In contrast,
LIF had no e¡ect on mast cell growth when BMMC were
cultured in the absence of ¢broblasts (data not shown).
Since the receptor for LIF is composed of a LIF-speci¢c
receptor subunit (LIFR) and a signal transduction molecule,
gp130 [14,15], expression of these molecules was examined in
BMMC and 3T3 ¢broblasts in order to investigate the mech-
Fig. 1. LIF enhanced mast cell growth in the mast cell/¢broblast
co-culture system. 3U104 BMMC were seeded and co-cultured with
3T3 ¢broblasts in the presence of a series of concentrations of LIF.
Mast cell numbers (A) and histamine contents (B) were determined
on day 6. Data are mean þ S.E.M. of three independent experiments
done in duplicate (*P6 0.05).
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anisms of LIF-induced BMMC proliferation. Western blot
analysis revealed that 3T3 ¢broblasts express both LIFR
and gp130, whereas mast cells express neither LIFR nor
gp130 (Fig. 2). These results indicate that LIF indirectly en-
hances mast cell growth via 3T3 ¢broblasts.
3.2. Tyrosine phosphorylation of gp130 and Stat3 in the
LIF-stimulated 3T3 ¢broblasts
Binding of LIF and LIFR induces heterodimerization of
LIFR and gp130 [16], followed by activation of a Janus kinase
(JAK)^Stat pathway [17]. In LIFR and gp130-mediated signal
transduction, Stat3 is known to play a central role [17], acti-
vation of gp130 and Stat3 was determined in LIF-stimulated
3T3 ¢broblasts by using immunoprecipitation and Western
blot. LIF induced tyrosine phosphorylation and heterodimer-
ization of both LIFR and gp130 5 min after stimulation (Fig.
3). Tyrosine phosphorylation of Stat3 was also detected in
LIF-stimulated 3T3 ¢broblasts 5 min after stimulation (Fig.
4). On the other hand, LIF failed to phosphorylate gp130 and
Stat3 in BMMC (data not shown).
When the 3T3 ¢broblast clone that stably expressed exog-
enous HA-Stat3 was established by the electroporation meth-
od, and BMMC were co-cultured with the stable Stat3 trans-
fectant, the Stat3-transfected ¢broblasts signi¢cantly
enhanced mast cell growth compared with mock-transfected
¢broblasts (Fig. 5).
3.3. Dominant-negative Stat3 blocked LIF-induced mast cell
growth
To con¢rm the role of Stat3 in the LIF-induced mast cell
growth, we established two 3T3 ¢broblast clones that express
exogenous dominant-negative Stat3 (HA-Stat3D and HA-
Stat3F) and examined the e¡ect of these mutants Stat3 on
LIF-induced mast cell growth. When the HA-Stat3D- and
HA-Stat3F-transfected ¢broblasts were used for the feeder
layer in the BMMC/3T3 ¢broblast co-culture system, both
HA-Stat3D- and HA-Stat3F-transfected ¢broblasts failed to
mediate LIF-induced mast cell growth compared with mock-
transfected ¢broblasts (Fig. 6). Tyrosine phosphorylation of
Stat3 was undetectable in HA-Stat3F-transfected ¢broblasts
even when stimulated by LIF (Fig. 7).
Fig. 2. Detection of LIFR and gp130 in BMMC and 3T3 ¢bro-
blasts. Cell lysates were prepared from 3T3 ¢broblasts and BMMC,
and 10 Wg of these samples were analyzed by immunoblotting using
anti-mouse LIFR and gp130 polyclonal antibody.
Fig. 3. LIF-induced tyrosine phosphorylation and heterodimeriza-
tion of LIFR and gp130. 3T3 ¢broblasts were stimulated with 100
ng/ml of LIF for indicated intervals, then lysed and immunoprecipi-
tated by using anti-gp130 polyclonal antibody and Protein G-Se-
pharose. These antigen^antibody complexes were collected and ana-
lyzed by immunoblotting. Upper panel: immunoblotting with HRP-
conjugated anti-phosphotyrosine antibody (4G10), middle panel: im-
munoblotting with anti-gp130 antibody, and lower panel: immuno-
blotting with anti-LIFR antibody.
Fig. 4. LIF-induced tyrosine phosphorylation of Stat3 in 3T3 ¢bro-
blasts. 3T3 ¢broblasts were stimulated with 100 ng/ml of LIF, then
lysed and analyzed using PhosphoPlus0 Stat3 (Tyr705) Antibody kit
according to the manufacturer’s instructions.
Fig. 5. Stat3-transfected ¢broblasts enhanced mast cell growth in
the co-culture. BMMC were co-cultured with mock-transfected ¢-
broblasts and Stat3-transfected ¢broblasts, and histamine contents
were determined on day 6. Data are mean þ S.E.M. of three inde-
pendent experiments done in duplicate (*P6 0.05).
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4. Discussion
Through the characterization of mast cell growth-enhancing
activity found in KCMH-1 cell conditioned medium, we have
previously identi¢ed LIF as a mast cell growth-enhancing
factor. Studies on the action of LIF suggested that LIF-in-
duced mast cell proliferation in the co-culture was not by
direct action on mast cells, but was mediated by the 3T3
¢broblasts in the BMMC/3T3 ¢broblast co-culture system.
To address the molecular mechanisms for LIF-induced mast
cell growth-enhancement in 3T3 ¢broblasts, we investigated
the expression of LIFR and gp130 in 3T3 ¢broblasts and
BMMC by Western blotting. BMMC express neither LIFR
nor gp130, whereas 3T3 ¢broblasts expressed both LIFR and
gp130, clearly indicating the indirect action of LIF for mast
cell growth-enhancement.
Gp130 is a common signal transduction molecule shared by
the receptors for IL-6, IL-11, oncostatin M, ciliary neurotro-
phic factor, and cardiotrophin 1. The signal from gp130 is
transduced by two di¡erent pathways; one is mediated by
phosphorylation of JAK followed by the activation of Stat3,
and the other mediated with mitogen-activated protein kinase,
extracellular signal-regulated kinase (ERK). To assess the me-
diation of Stat3 in LIF-induced mast cell proliferation, we
made two forms of Stat3 mutant that block the activation
of Stat3 in a dominant-negative manner. Mast cell prolifera-
tion-signal induced by LIF was mediated through the Stat3
molecule, since both mutants of Stat3, Stat3D and Stat3F
completely and speci¢cally blocked LIF-induced mast cell
growth-enhancement (Fig. 6). In addition, an increased ex-
pression of Stat3 in the 3T3 ¢broblasts enhanced mast cell
growth in the co-culture system (Fig. 5), although transient
expression of ERK in the 3T3 ¢broblasts failed to enhance
mast cell growth (data not shown), suggesting that activation
of the Stat3 pathway is enough to induce mast cell prolifer-
ation.
LIF has a diversity of functions to various types of cells.
LIF was ¢rst identi¢ed as a factor causing di¡erentiation of
myeloid leukemic M1 cells into macrophages in vitro and in
vivo [18]. LIF also induces di¡erentiation of megakaryocytes
in vivo [19], production of acute phase proteins by hepato-
cytes [20], cholinergic neuronal di¡erentiation [21], proin£am-
matory cytokine expression in a broad spectrum of cell types
[22], and ear swelling and leukocyte in¢ltration in the mouse
ear in vivo [23]. On the other hand, LIF suppresses sponta-
neous di¡erentiation of murine embryonic stem cells in vitro
[24]. Recently, Shih et al. have revealed that LIF induces
hematopoietic stem cell expansion in a stromal-based culture
system, and this action of LIF is indirect and mediated by
induction of growth factors for hematopoietic stem cells in
stromal cells [25]. Furthermore, by analysis of the supernatant
of LIF-treated stromal cells, they have ruled out the contri-
butions by six known cytokines, IL-3, IL-6, granulocyte mac-
rophage-colony stimulating factor, SCF, £t-3 ligand and
thrombopoietin, suggesting involvement of a novel growth
factor. Our ¢nding resembles to their facts in that LIF induces
bone marrow-derived cell proliferation in a stromal-based cul-
ture system. In this study, a molecule causing mast cell growth
which is induced on 3T3 ¢broblasts has not yet been de¢ned.
One possible cause for the mast cell growth is an enhanced
expression of SCF in 3T3 ¢broblasts ; another possibility is
the expression of an unknown mast cell growth factor on the
surface of 3T3 ¢broblasts. This remains to be determined.
Although we have identi¢ed LIF as a keratinocyte-derived
mast cell growth-enhancing factor [8], LIF is also produced
from activated mast cells [26]. Mast cells, thus, may regulate
their proliferation by themselves through the secretion of LIF.
In conclusion, we demonstrated that LIF-induced mast cell
growth in the mast cell/¢broblast co-culture is mediated not
by direct action of LIF to mast cells but by the indirect path-
way via 3T3 ¢broblasts through activating Stat3 signaling
pathway in 3T3 ¢broblasts.
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